Navigation Links
Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator
Date:11/9/2011

MINNEAPOLIS, Nov., 9, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the issuance of United States Patent No. 8,046,082 covering the stimulator used in the Urgent® PC Neuromodulation System.  The Urgent PC Neuromodulation System is an office-based, non-surgical system, used to treat overactive bladder syndrome (OAB) and the associated symptoms of urinary urge incontinence, urinary urgency and urinary frequency. The new patent covers the reusable Urgent® PC stimulator.  When connected to a thin needle electrode near the ankle to access the tibial nerve, the stimulator delivers current to the sacral nerve plexus that controls bladder and pelvic floor function.

"This newly-issued patent further strengthens our patent position on the Urgent PC System and reinforces our commitment to this product," said David Kaysen, President and CEO of Uroplasty.  "We are very pleased that the United States Patent Office has awarded this apparatus patent on the unique stimulator used in our Urgent PC System.  Our broad intellectual property portfolio, applicable to the Urgent PC System and its components, now includes apparatus, method, and system patents."

About Uroplasty, Inc.Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in

The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com. For Further Information:Uroplasty, Inc.

EVC Group David Kaysen, President and CEO, or

Doug Sherk/Jenifer Kirtland (Investors),
415.568.9349 Medi Jiwani, Vice President, CFO, Treasurer

Chris Gale (Media), 646.201.5431952.426.6140
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
2. Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
3. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
4. Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009
5. Uroplasty Reports Results for Second Quarter FY2010
6. Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference
7. Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplastys Urgent® PC Neuromodulation System
8. Uroplasty to Present at The 5th Annual JMP Securities Healthcare Conference
9. Uroplasty to Issue Second Quarter 2011 Results on October 27, 2010
10. Uroplasty Reports Financial Results for the Second Quarter FY2011
11. Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), ... quarter and full year ended December 31, 2015. ... a transformational year for Vanda with the continued growth ... approval of HETLIOZ for Non-24," said Mihael H. Polymeropoulos, ... to our U.S. product portfolio builds on this success ...
(Date:2/10/2016)... --> --> This press release is intended for ... Japan .  --> A separate press release has been prepared ... Shire continues to strengthen its presence in ... continues to strengthen its presence in Japan ... continues to strengthen its presence in Japan ...
(Date:2/10/2016)... A new report from business intelligence provider GBI Research ... Alzheimer,s disease market will more than double from just under $5 billion in ... Rate (CAGR) of 11%. Canada , France ... Spain , the UK, and Japan , and ... --> Canada , France , ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is excited to ... water brand owners that topped the list as a result of their commitment to ... premier brand was Tibet 5100, a top notch water company that specializes in providing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 ... more than 200 of the country’s top healthcare executives to share insights on ... benefit of the Forum is the provider-centric perspective, experience, expertise and strategy shared ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience ... across their network of laboratory service centers across the country. Launched in April of ... in the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the Ohio Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's ... Convention Center. , As the longest running and largest worker's compensation event ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... February 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm | ... | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: http://www.facebook.com/uspolesportsfederation ...
Breaking Medicine News(10 mins):